Atherotech's VAP (Vertical Auto Profile) test raises lipid medication use
This article was originally published in Clinica
Executive Summary
Atherotech reports that its lipoprotein subclass test could boost the use of lipid-lowering therapy in high-risk patients with type 2 diabetes.